Safety and efficacy of quetiapine in bipolar depression

Annals of Pharmacotherapy

Volumn 43, Issue 11, 2009, Pages 1848-1856

  Bogart, Gregory T ^a   Chavez, Benjamin ^b  

^a ENGLEWOOD HOSPITAL AND MEDICAL CENTER   (United States)

^b RUTGERS UNIVERSITY   (United States)

Author keywords

Bipolar depression; Bipolar disorder; Quetiapine

Indexed keywords

ENZYME INHIBITOR; LITHIUM; LORAZEPAM; PAROXETINE; QUETIAPINE; ZOLPIDEM;

AKATHISIA; ANXIETY; ANXIETY DISORDER; BIPOLAR DEPRESSION; BIPOLAR DISORDER; CLINICAL ASSESSMENT TOOL; CLINICAL TRIAL; CONTROLLED DRUG RELEASE; DEPRESSION; DISABILITY; DRUG DOSE COMPARISON; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG SAFETY; DRUG WITHDRAWAL; ENZYME SUBSTRATE; EVENING DOSAGE; EXTRAPYRAMIDAL SYMPTOM; HAMILTON ANXIETY SCALE; HUMAN; INSOMNIA; MONTGOMERY ASBERG DEPRESSION RATING SCALE; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; REMISSION; REVIEW; SEDATION; SIDE EFFECT; SINGLE DRUG DOSE; SLEEP; SOMNOLENCE; TREATMENT OUTCOME; XEROSTOMIA;

BIPOLAR DISORDER; CLINICAL TRIALS AS TOPIC; DIBENZOTHIAZEPINES; HUMANS; PSYCHIATRIC STATUS RATING SCALES; SLEEP DISORDERS; TREATMENT OUTCOME;

EID: 70449719321     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1M193     Document Type: Review

References (30)

1. Ten Have M, Vollerbergh W, Bijl R, Nolen WA. Bipolar disorder in the general population in The Netherlands (prevalence, consequences and care utilization): results from The Netherlands Mental Health Survey and Incidence Study (NEMESIS). J Affect Disord 2002;68:203-213 (Pubitemid 34628327)
2. Merikangas KR, Akiskal HS, Angst J, et al. Lifetime and 12-month prevalence of bipolar spectrum in the National Comorbidity Survey replication. Arch Gen Psychiatry 2007;64:543-552 (Pubitemid 46718287)
3. Hirschfield RMA, Calabrese JR, Weissman MM, et al. Screening for bipolar disorder in the community. J Clin Psychiatry 2003;64:53-59
4. Baldessarini RJ, Pompili M, Tondo L. Suicide in bipolar disorder: risks and management. CNS Spectr 2006;11:465-471 (Pubitemid 43938818)
5. Judd LL, Akiskal HS, Schettler PJ, et al. The long-term natural history of the weekly symptomatic status of bipolar I disorder. Arch Gen Psychiatry 2002;59:530-537
6. Post RM, Denicoff KD, Leverich GS, et al. Morbidity in 258 bipolar outpatients followed for 1 year with daily prospective ratings on the NIMH life chart method. J Clin Psychiatry 2003;64:680-690
7. Diagnostic and statistical manual of mental disorders. 4th ed., text revision. Washington, DC: American Psychiatric Association, 2000.
8. Sachs GS, Nierenberg AA, Calabrese JR, et al. Effectiveness of adjunctive antidepressant treatment for bipolar depression. N Engl J Med 2007; 356:1711-1722
9. Fountoulakis KN, Grunze H, Panagiotidis P, Kaprinis G. Treatment of bipolar depression: an update. J Affect Disord 2008;109:21-34.
10. Fountoulakis KN, Vieta E. Treatment of bipolar disorder: a systematic review of available data and clinical perspectives. Int J Neuropsychopharmacol 2008;11:999-1029.
11. Product information. Seroquel XR (quetiapine fumarate extended-release tablets). Wilmington, DE: AstraZeneca Pharmaceuticals LP, January 2009.
12. Product information. Seroquel (quetiapine fumarate). Wilmington, DE: AstraZeneca Pharmaceuticals LP, January 2009.
13. Calabrese JR, Keck PE, Macfadden W, et al. A randomized, doubleblind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression. Am J Psychiatry 2005;162:1351-1360 (Pubitemid 40905587)
14. Thase ME, Macfadden W, Weisler RH, et al. Efficacy of quetiapine monotherapy in bipolar I and II depression: a double-blind, placebo-controlled study (The BOLDER II Study). J Clin Psychopharmacol 2006; 26:600-609 (Pubitemid 44772737)
15. Young AH, McElroy S, Chang W, Olausson B, Paulsson B, Brecher M. A double-blind, placebo-controlled study with acute and continuation phase of quetiapine in adults with bipolar depression (EMBOLDEN I). Presented at: 13th Annual Meeting of the International Society of Pharmacoeconomics and Outcomes Research, May 3-7, 2008, Toronto, Ontario, Canada.
16. McElroy S, Chang W, Olausson B, et al. A double-blind, placebo controlled study of quetiapine and paroxetine in adults with bipolar depression (EMBOLDEN II). Presented at: 48th Annual New Clinical Drug Evaluation Meeting, May 27-30, 2008, Phoenix, AZ.
17. Suppes T, Datto C, Minkwitz M, Nordenhem A, Walker C, Darko D. Effectiveness of the extended release formulation of quetiapine as monotherapy for the treatment of acute bipolar depression. Presented at: 48th Annual New Clinical Drug Evaluation Meeting, May 27-30, 2008, Phoenix, AZ.
18. Hirschfeld RMA, Weisler RH, Raines SR, Macfadden W. Quetiapine in the treatment of anxiety patients with bipolar I or II depression: a secondary analysis from a randomized, double-blind, placebo-controlled study. J Clin Psychiatry 2006;67:355-362
19. Endicott J, Rajagopalan K, Minkwitz M, Macfadden W. A randomized, double blind, placebo-controlled study of quetiapine in the treatment of bipolar I and II depression: improvements in quality of life. Int Clin Psychopharmacol 2007;22:29-37. (Pubitemid 44950765)
20. Vieta E, Calabrese JR, Goikolea JM, Raines S, Macfadden W. Quetiapine monotherapy in the treatment of patients with bipolar I or II depression and a rapid-cycling disease course: a randomized, double-blind, placebo-controlled study. Bipolar Disord 2007;9:413-425 (Pubitemid 46865372)
21. Weisler RH, Calabrese JR, Thase ME, et al. Efficacy of quetiapine monotherapy for the treatment of depressive episodes in bipolar disorder: a post hoc analysis of combined results from two double-blind, randomized, placebo-controlled studies. J Clin Psychiatry 2008;69:769-782
22. Endicott J, Paulsson B, Gustafsson U, Schiöler H, Hassan M. Quetiapine monotherapy in the treatment of depressive episodes of bipolar I and II disorder: improvements in quality of life and quality of sleep. J Affect Disord 2008;111:306-319
23. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979;134:382-389 (Pubitemid 9136500)
24. Calabrese JR, Bowden BL, Sachs GS, Ascher JA, Monaghan E, Rudd GH. A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. Lamictal 602 Study group. J Clin Psychiatry 1999;60:79-88. (Pubitemid 29104383)
25. Goldsmith DR, Wagstaff AJ, Ibbotson T, Perry CM. Lamotrigine: a review of its use in bipolar disorder. Drugs 2003;63:2029-2050 (Pubitemid 37229087)
26. Brown EB, McElory SL, Keck PE Jr, et al. A 7-week, randomized, double- blind trial of olanzapine/fluoxetine combinations versus lamotrigine in the treatment of bipolar I depression. J Clin Psychiatry 2006;67:1025-1033 (Pubitemid 44230872)
27. Tohen M, Vieta E, Calabrese J, et al. Efficacy of olanzapine and olanzapine- fluoxetine combination in the treatment of bipolar I depression. Arch Gen Psychiatry 2003;60:1079-1088 (Pubitemid 37429647)
28. Shi L, Manjoshi MA, Swindle R, et al. Effects of olanzapine alone and olanzapine/fluoxetine combination in health-related quality of life in patients with bipolar depression: secondary analyses of a double-blind, placebo-controlled, randomized clinical trial. Clin Ther 2004;26:125-134 (Pubitemid 38241530)
29. American Diabetes Association. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 2004;27: 595-601.
30. Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005; 353:1209-1223 (Pubitemid 41345943)